Endometrial Hyperplasia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: END062 MIFTS: 47	Endometrial Hyperplasia Categories: Cancer diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Endometrial Hyperplasia

MalaCards integrated aliases for Endometrial Hyperplasia:

Name: Endometrial Hyperplasia ¹¹ ⁵³ ⁴³ ¹⁴ ⁷⁵

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0080365

MeSH ⁴³ D004714

Sources

Summaries for Endometrial Hyperplasia

Disease Ontology: ¹¹ An uterine benign neoplasm that is characterized by excessive proliferation of the cells of the endometrium.

MalaCards based summary: Endometrial Hyperplasia is related to endometrial adenocarcinoma and adenomyosis. An important gene associated with Endometrial Hyperplasia is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gene expression (Transcription) and Signal Transduction. The drugs Medroxyprogesterone acetate and Contraceptive Agents, Male have been mentioned in the context of this disorder. Affiliated tissues include uterus, pituitary and ovary, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)

Wikipedia: ⁷⁵ Endometrial hyperplasia is a condition of excessive proliferation of the cells of the endometrium, or... more...

Sources

Related Diseases for Endometrial Hyperplasia

Diseases related to Endometrial Hyperplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)

#	Related Disease	Score	Top Affiliating Genes
1	endometrial adenocarcinoma	31.1	PTEN PGR MSH6 MSH2 MLH1 KRAS
2	adenomyosis	31.0	PTEN KRAS ESR1 CYP19A1 CTNNB1
3	myoma	30.8	PGR KRAS ESR1 CYP19A1
4	adenocarcinoma	30.7	PTEN MSH6 MSH2 MLH1 KRAS CTNNB1
5	estrogen excess	30.7	PTEN PGR ESR2 ESR1 CYP19A1
6	endometriosis	30.7	PTEN PGR ESR2 ESR1 CYP19A1 CYP17A1
7	vaginal discharge	30.7	PGR ESR1 CYP19A1
8	adenomyoma	30.6	PGR MLH1 ESR1 CTNNB1
9	lynch syndrome 1	30.6	MSH6 MSH2 MLH1
10	ovarian cyst	30.6	PGR MSH2 ESR2 ESR1 CYP19A1
11	leiomyoma, uterine	30.4	PGR ESR2 ESR1 CYP19A1
12	mismatch repair cancer syndrome 1	30.4	PTEN MSH6 MSH2 MLH1 CTNNB1
13	lynch syndrome	30.3	PTEN PGR MSH6 MSH2 MLH1 KRAS
14	vaginal cancer	30.3	PTEN PGR ESR1
15	infertility	30.3	PGR MLH1 ESR2 ESR1 CYP19A1 AR
16	hyperandrogenism	30.3	CYP19A1 CYP17A1 AR
17	papillary serous adenocarcinoma	30.3	PGR KRAS ESR1
18	adenosarcoma	30.3	PGR MKI67 ESR1
19	mismatch repair cancer syndrome	30.2	PTEN MSH6 MSH2 MLH1 KRAS CTNNB1
20	carcinosarcoma	30.2	PTEN PGR KRAS CTNNB1
21	pelvic organ prolapse	30.2	ESR2 ESR1 CTNNB1
22	cystadenocarcinoma	30.2	PTEN PGR KRAS ESR2
23	inherited cancer-predisposing syndrome	30.2	PTEN MSH6 MSH2 MLH1
24	bap1 tumor predisposition syndrome	30.2	PTEN MSH6 MSH2 MLH1
25	endometrial stromal sarcoma	30.2	PGR ESR2 ESR1 CYP19A1
26	cervical adenocarcinoma	30.2	PGR MKI67 KRAS ESR1
27	teratoma	30.1	PTEN KRAS ESR1 CTNNB1
28	leydig cell tumor	30.1	ESR1 CYP19A1 CYP17A1
29	appendix adenocarcinoma	30.1	MSH6 KRAS
30	acne	30.1	CYP19A1 CYP17A1 AR
31	leiomyoma	30.0	PGR MKI67 ESR2 ESR1 CYP19A1 CYP17A1
32	meningioma, familial	30.0	PTEN PGR MKI67 ESR1 CTNNB1
33	serous cystadenocarcinoma	29.9	PTEN PGR MSH6 MSH2 MLH1 KRAS
34	estrogen-receptor positive breast cancer	29.9	PTEN PGR ESR2 ESR1 CYP19A1 AR
35	adenoma	29.7	MSH6 MSH2 MLH1 MKI67 KRAS CTNNB1
36	uterine carcinosarcoma	29.7	PTEN MSH6 MSH2 MLH1 KRAS ESR1
37	premature menopause	29.6	PTEN PGR ESR2 ESR1 CYP19A1 CYP17A1
38	uterine corpus cancer	29.6	PTEN PGR MSH6 MSH2 MLH1 KRAS
39	endometrial cancer	29.5	PTEN PGR NCOA3 NCOA1 MSH6 MSH2
40	ovarian disease	29.5	PTEN PGR ESR2 ESR1 CYP19A1 CYP17A1
41	ovarian cancer	28.0	RBP1 PTEN PGR NCOA3 MSH6 MSH2
42	breast cancer	27.5	PTEN PGR NCOR1 NCOA3 NCOA1 MSH6
43	polycystic ovary syndrome	10.6
44	polycystic ovary syndrome 1	10.5
45	breast duct papilloma	10.4	PTEN PGR
46	nipple carcinoma	10.4	PGR ESR1
47	bartholin's gland adenoma	10.4	PGR ESR1
48	uterine corpus adenosarcoma	10.4	PGR ESR1
49	breast mucinous cystadenocarcinoma	10.4	PGR ESR1
50	bartholin's gland benign neoplasm	10.4	PGR ESR1

Graphical network of the top 20 diseases related to Endometrial Hyperplasia:

Sources

Symptoms & Phenotypes for Endometrial Hyperplasia

GenomeRNAi Phenotypes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

²⁵ (show all 24)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.2	AR CABLES1 CDK2 CTNNB1 CYP17A1 CYP19A1
2	no effect	GR00402-S-2	10.2	AR CABLES1 CDK2 CTNNB1 CYP17A1 CYP19A1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-102	10.02	CABLES1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	10.02	NCOR1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	10.02	MSH2
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	10.02	KRAS
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-132	10.02	NCOR1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-14	10.02	MSH2
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-145	10.02	CABLES1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	10.02	MSH2
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	10.02	CABLES1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	10.02	MSH2
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	10.02	CABLES1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-197	10.02	CABLES1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	10.02	CABLES1
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-212	10.02	NCOR1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.02	MSH2
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	10.02	KRAS
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-24	10.02	NCOR1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-4	10.02	NCOR1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-53	10.02	MSH2 NCOR1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.02	CABLES1 KRAS
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-78	10.02	CABLES1
24	Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)	GR00104-A-0	9.55	ESR1 ESR2 MKI67 MSH2 PTEN

MGI Mouse Phenotypes related to Endometrial Hyperplasia:

⁴⁵ (show all 24)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.5	AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
2	neoplasm	MP:0002006	10.46	AR CABLES1 CDK2 CTNNB1 ESR1 ESR2
3	endocrine/exocrine gland	MP:0005379	10.39	AR CABLES1 CDK2 CTNNB1 CYP19A1 ESR1
4	nervous system	MP:0003631	10.38	AR CABLES1 CTNNB1 CYP19A1 ESR1 ESR2
5	growth/size/body region	MP:0005378	10.37	AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
6	normal	MP:0002873	10.35	AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
7	cellular	MP:0005384	10.33	AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
8	muscle	MP:0005369	10.32	AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
9	liver/biliary system	MP:0005370	10.32	AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
10	immune system	MP:0005387	10.3	AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
11	behavior/neurological	MP:0005386	10.25	AR CABLES1 CTNNB1 CYP17A1 CYP19A1 ESR1
12	renal/urinary system	MP:0005367	10.24	AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
13	adipose tissue	MP:0005375	10.21	AR CYP17A1 CYP19A1 ESR1 ESR2 NCOA1
14	reproductive system	MP:0005389	10.2	AR CABLES1 CDK2 CTNNB1 CYP17A1 CYP19A1
15	embryo	MP:0005380	10.19	AR CDK2 CTNNB1 ESR1 KRAS NCOA1
16	digestive/alimentary	MP:0005381	10.18	AR CTNNB1 CYP19A1 ESR1 ESR2 KRAS
17	cardiovascular system	MP:0005385	10.17	AR CDK2 CTNNB1 CYP17A1 CYP19A1 ESR1
18	limbs/digits/tail	MP:0005371	10.11	AR CTNNB1 ESR1 ESR2 KRAS PGR
19	pigmentation	MP:0001186	10.09	AR CTNNB1 CYP19A1 KRAS PTEN RBP1
20	hearing/vestibular/ear	MP:0005377	10.08	CTNNB1 CYP17A1 CYP19A1 ESR2 KRAS NCOA3
21	hematopoietic system	MP:0005397	10.03	AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2
22	skeleton	MP:0005390	10	AR CTNNB1 CYP17A1 CYP19A1 ESR1 ESR2
23	mortality/aging	MP:0010768	9.8	AR CDK2 CTNNB1 CYP17A1 ESR1 ESR2
24	integument	MP:0010771	9.5	AR CDK2 CTNNB1 CYP19A1 ESR1 ESR2

Sources

Drugs & Therapeutics for Endometrial Hyperplasia

Drugs for Endometrial Hyperplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Medroxyprogesterone acetate

Approved, Investigational

Phase 4

520-85-4, 71-58-9

6279 10631

Contraceptive Agents, Male

Phase 4

Estrogens, Conjugated (USP)

Phase 4

BIRC5 protein, human

Phase 4

Bazedoxifene

Approved, Investigational

Phase 3

198481-32-2

154257

Raloxifene

Approved, Investigational

Phase 3

82640-04-8, 84449-90-1

5035

Metformin

Approved

Phase 2, Phase 3

1115-70-4, 657-24-9

4091

Levonorgestrel

Approved, Investigational

Phase 2, Phase 3

797-63-7

13109

Dydrogesterone

Approved, Investigational, Withdrawn

Phase 2, Phase 3

152-62-5

9051

Progesterone

Approved, Vet_approved

Phase 3

57-83-0

5994

Estradiol

Approved, Investigational, Vet_approved

Phase 2, Phase 3

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 2, Phase 3

28014-46-2

Letrozole

Approved, Investigational

Phase 2, Phase 3

112809-51-5

3902

Ethinylestradiol

Approved

Phase 2, Phase 3

57-63-6

5991

Cyproterone acetate

Approved, Investigational

Phase 2, Phase 3

427-51-0

9880

Estrogen Receptor Modulators

Phase 3

Selective Estrogen Receptor Modulators

Phase 3

Rosuvastatin Calcium

Phase 2, Phase 3

147098-20-2

Antimetabolites

Phase 2, Phase 3

Calcium, Dietary

Phase 2, Phase 3

Hypolipidemic Agents

Phase 2, Phase 3

Anticholesteremic Agents

Phase 2, Phase 3

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 2, Phase 3

Lipid Regulating Agents

Phase 2, Phase 3

Progestins

Phase 3

Estradiol 3-benzoate

Phase 2, Phase 3

Estradiol 17 beta-cypionate

Phase 2, Phase 3

Cyproterone

Phase 2, Phase 3

2098-66-0

5284537

Androgens

Phase 2, Phase 3

Androgen Antagonists

Phase 2, Phase 3

Cyproterone acetate, ethinyl estradiol drug combination

Phase 2, Phase 3

Calcium

Nutraceutical

Phase 2, Phase 3

7440-70-2

271

Norethisterone

Approved

Phase 2

68-22-4

199472 6230

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Exemestane

Approved, Investigational

Phase 2

107868-30-4

60198

Genistein

Investigational

Phase 2

446-72-0

5280961

Norethindrone Acetate

Phase 2

541197

Soy Bean

Phase 2

Gonadotropins, Pituitary

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Hormones

Phase 2

Hormone Antagonists

Phase 2

Estrogens

Phase 2

Estrogen Receptor Antagonists

Phase 2

Estrogen Antagonists

Phase 2

Aromatase Inhibitors

Phase 2

Formaldehyde

Approved, Vet_approved

50-00-0

712

Tamoxifen

Approved

10540-29-1, 54965-24-1

2733526

Interventional clinical trials:

(show top 50) (show all 67)

#	Name	Status	NCT ID	Phase	Drugs
1	A Multicenter Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia	Completed	NCT01074892	Phase 4	Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
2	The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia	Completed	NCT02872818	Phase 4	17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
3	Randomized, Blinded Trial Comparing Vaginal Estrogens on Pelvic Organ Prolapse Patients	Completed	NCT03032848	Phase 4	Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
4	A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women	Completed	NCT00808132	Phase 3	bazedoxifene 20 mg/ conjugated estrogens 0.45 mg;bazedoxifene 20 mg/ conjugated estrogens 0.625 mg;bazedoxifene 20 mg;conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg;Placebo
5	A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy And Safety Study Of Bazedoxifene/Conjugated Estrogens Combinations For Prevention Of Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women	Completed	NCT00242710	Phase 3	Bazedoxifene/Conjugated Estrogen;CE 0.45 mg/MPA 1.5mg
6	Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia	Completed	NCT04491682	Phase 2, Phase 3	Megestrol Acetate;Rosuvastatin
7	A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women	Completed	NCT00675688	Phase 3	Bazedoxifene/Conjugate Estrogens (CE);Raloxifene;Placebo
8	Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits	Completed	NCT00490087	Phase 3
9	Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia	Completed	NCT03241888	Phase 2, Phase 3	Megestrol Acetate
10	The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial.	Recruiting	NCT04385667	Phase 2, Phase 3	Oral Megesterol 160 mg daily
11	Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia	Recruiting	NCT03675139	Phase 2, Phase 3	Medroxyprogesterone Acetate;Dydrogesterone 10 MG
12	MicroRNAs as Biomarkers of Predicting Future Endometrial Malignancy and Longitudinal Follow-up With Randomized Intervention in Women With Endometrial Hyperplasia Without Atypia	Recruiting	NCT05292573	Phase 3	Metformin
13	Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia: A Non-Inferiority Study	Recruiting	NCT04897217	Phase 3	Megestrol Acetate;Levonorgestrel Drug Implant
14	Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma	Recruiting	NCT03463252	Phase 2, Phase 3	Progesterone;GnRH agonist
15	Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study	Recruiting	NCT05316493	Phase 2, Phase 3	Megestrol Acetate 160 MG Oral Tablet;Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
16	Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole vs Ethinylestradiol Cyproterone Plus Metformin in Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment	Recruiting	NCT05316935	Phase 2, Phase 3	GnRHa;Letrozole 2.5mg;Diane-35;MET
17	A Randomized Controlled Pilot Study of Polyethylene Glycol Loxenatide Plus LNG-IUS in Women With Endometrial Atypical Hyperplasia	Recruiting	NCT05172999	Phase 2, Phase 3	Polyethylene Glycol Loxenatide
18	Comparing Metformin Plus Megestrol Acetate With Megestrol Acetate Alone as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia	Terminated	NCT04607252	Phase 2, Phase 3	Metformin plus Megestrol acetate;Megestrol Acetate
19	Megestrol Acetate Versus Liraglutide Plus Megestrol Acetate in Obese Women With Endometrial Atypical Hyperplasia: A Randomized Controlled Pilot Clinical Study	Withdrawn	NCT04683237	Phase 2, Phase 3	Liraglutide Injection;Megestrol Acetate 160 MG
20	Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System:Single Arm, Prospective Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2006)	Unknown status	NCT01234818	Phase 2
21	A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium	Unknown status	NCT01686126	Phase 2	Levonorgestrel;Metformin
22	Efficacy & Tolerability of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Replacement Therapy - Phase II Comparative Study	Unknown status	NCT00919919	Phase 2	progesterone;activella
23	Surgicel® Versus Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding (HMB): Randomised Controlled Trial	Unknown status	NCT03176992	Phase 2	SURGICEL®
24	The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy	Unknown status	NCT02335203	Phase 2	Depot medroxyprogesterone acetate
25	Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate	Completed	NCT00483327	Phase 2	Megestrol Acetate
26	Effect of Genistein on Endometrial Hyperplasia	Completed	NCT00453960	Phase 2	Norethisterone Acetate
27	Soy Estrogen Alternative Study (SEA)	Completed	NCT00000612	Phase 2	estrogens, conjugated
28	A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore	Recruiting	NCT05492487	Phase 2	Mirena;Megace
29	Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy	Recruiting	NCT03671811	Phase 2	Megestrol Acetate
30	Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer	Recruiting	NCT02397083	Phase 2	Everolimus
31	A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma	Active, not recruiting	NCT00788671	Phase 2
32	Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer	Active, not recruiting	NCT03300557	Phase 2	Exemestane
33	A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation	Terminated	NCT00503581	Phase 2	Megestrol Acetate
34	A Two-Part Study of the Treatment of Atypical Endometrial Hyperplasia: Part A: A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate Versus Depoprovera	Terminated	NCT00003179	Phase 2	medroxyprogesterone
35	Levonorgestrel Containing Intrauterine Device in the Treatment of Endometrial Hyperplasia Without Atypia	Withdrawn	NCT00123175	Phase 1, Phase 2
36	A Phase II Head-to-Head Comparison of Fertility-Sparing Approaches to Treat Complex Atypical Hyperplasia of the Edometrium: Megestrol Versus Levonorgestrel-Releasing Intrauterine System (LNG-IUS)	Withdrawn	NCT01943058	Phase 2	megestrol acetate
37	Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)	Active, not recruiting	NCT00892866	Phase 1
38	Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study	Unknown status	NCT02412072
39	Concurrent Endometrial Cancer With Endometrial Hyperplasia or Endometrial Intraepithelial Neoplasia - Focus on Risk Factors Analysis	Unknown status	NCT01273636
40	The Relation Between Serum Irisin Hormone Level and Endometrial Hyperplasia	Unknown status	NCT02903797
41	THE EFFECTIVENESS OF MONOPOLAR HOOC VERSUS PLASMAKINETIC BİPOLAR SPATULA USAGE DURING COLPOTOMY PROCESS IN PATIENTS UNDERGOİNG TOTAL LAPAROSCOPIC HYSTERECTOMY	Unknown status	NCT04191603
42	Role of Senescence in the Development of Endometrial Cancer	Unknown status	NCT03338985
43	Long-term Observation of Symptomatic Women With Uterine Fibroids Who Have Been Treated With Ulipristal Acetate: Findings on Symptomatology, Morphological Structure, Endometrial Patterns	Unknown status	NCT03972917
44	Metformin for the Treatment of Endometrial Hyperplasia	Completed	NCT01685762	Early Phase 1	Metformin
45	Women With Asymptomatic Endometrial Hyperplasia	Completed	NCT02100137
46	Pilot-study of OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer	Completed	NCT01961102
47	Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination: a Prospective Cohort Study	Completed	NCT03917147
48	Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors	Completed	NCT00339651
49	Vaginal Micronized Progesterone or Levonorgestrel-releasing Intrauterine System (LNG-IUS) for Treatment of Non-atypical Endometrial Hyperplasia: A Prospective Randomized Trial	Completed	NCT03992937		Vaginal Micronized Progesterone
50	Office Hysteroscopy in the Infertility Work-out: the Role of Endometrial Hyperplasia in Southern Italian Women	Completed	NCT03965585

Search NIH Clinical Center for Endometrial Hyperplasia

Cochrane evidence based reviews: endometrial hyperplasia

Sources

Genetic Tests for Endometrial Hyperplasia

Sources

Anatomical Context for Endometrial Hyperplasia

Organs/tissues related to Endometrial Hyperplasia:

MalaCards : Uterus, Pituitary, Ovary, Breast, Lymph Node, Cervix, Bone

Sources

Publications for Endometrial Hyperplasia

Articles related to Endometrial Hyperplasia:

(show top 50) (show all 3409)

#	Title	Authors	PMID	Year
1	Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. ⁵³ ⁶²	Pinkerton JV...Goldstein SR	20107426	2010
2	Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study. ⁵³ ⁶²	Akesson E...Gupta JK	20199355	2010
3	Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET. ⁵³ ⁶²	Tsujikawa T...Okazawa H	19759112	2009
4	Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome. ⁵³ ⁶²	Villavicencio A...Vega M	19631369	2009
5	Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia. ⁵³ ⁶²	Quddus MR...Lawrence WD	19696618	2009
6	[Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions]. ⁵³ ⁶²	Xiong Y...Zhou YF	20079187	2009
7	Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ⁵³ ⁶²	Barker LC...Crawford SM	19301987	2009
8	Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma. ⁵³ ⁶²	Gao Q...Ma D	19224164	2009
9	Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. ⁵³ ⁶²	Dobrzycka B...Kulikowski M	19419940	2009
10	Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. ⁵³ ⁶²	Lebeau A...Simon R	18720455	2008
11	Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. ⁵³ ⁶²	Tantbirojn P...Niruthisard S	18788685	2008
12	Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. ⁵³ ⁶²	Allison KH...Garica RL	18528284	2008
13	PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. ⁵³ ⁶²	Lacey JV...Sherman ME	18632658	2008
14	Labial aggressive angiomyxoma associated with endometrial hyperplasia and uterine leiomyoma: a case report and review of the literature. ⁵³ ⁶²	Larbcharoensub N...Tingthanatikul Y	18839858	2008
15	From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. ⁵³ ⁶²	Boruban MC...Blankstein J	18287870	2008
16	Expression of retinoic acid receptors in human endometrial carcinoma. ⁵³ ⁶²	Tanabe K...Yaegashi N	18271925	2008
17	Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia. ⁵³ ⁶²	Tsujikawa T...Fujibayashi Y	18250990	2008
18	Progressive derailment of cell cycle regulators in endometrial carcinogenesis. ⁵³ ⁶²	Horree N...Heintz AP	17483252	2008
19	Letrozole as primary therapy for endometrial hyperplasia in young women. ⁵³ ⁶²	Li HZ...Qiao J	17889878	2008
20	Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. ⁵³ ⁶²	Milam MR...Lu KH	17466036	2008
21	Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma. ⁵³ ⁶²	Witek A...Mazurek U	17561234	2007
22	Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement. ⁵³ ⁶²	Barroeta JE...Zhang PJ	17197901	2007
23	Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. ⁵³ ⁶²	Banno K...Aoki D	17089036	2006
24	Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers. ⁵³ ⁶²	Balmer NN...Singh M	16980945	2006
25	Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. ⁵³ ⁶²	McCampbell AS...Davies PJ	17085648	2006
26	Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. ⁵³ ⁶²	Villavicencio A...Vega M	16677694	2006
27	[Promoters of genes MTHFR from patients with hyperhomocysteinemia and PTEN from patients with malignant and benign endometrial and ovarian tumors]. ⁵³ ⁶²	Kovalenko TF...Patrushev LI	16909866	2006
28	Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications. ⁵³ ⁶²	Orlandi A...Czernobilsky B	16575402	2006
29	[Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma]. ⁵³ ⁶²	Zhao JH...Wu QY	16764775	2006
30	[Expressions of aromatase protein and sex hormone receptor in endometrial lesions]. ⁵³ ⁶²	Ma XX...Dong F	16831363	2006
31	Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. ⁵³ ⁶²	Vereide AB...Orbo A	16325240	2006
32	Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. ⁵³ ⁶²	Shang Y	16633364	2006
33	The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. ⁵³ ⁶²	Lai CH...Huang HJ	16493257	2006
34	CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer. ⁵³ ⁶²	Aban M...Altintas A	16515644	2006
35	Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium. ⁵³ ⁶²	Cirpan T...Ozsaran A	17009632	2006
36	Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. ⁵³ ⁶²	Rubatt JM...Broaddus RR	16099019	2005
37	Eosinophilic cell change of the endometrium: a possible relationship to mucinous differentiation. ⁵³ ⁶²	Moritani S...Silverberg SG	15803181	2005
38	Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. ⁵³ ⁶²	Baak JP...Lovslett K	15948123	2005
39	Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. ⁵³ ⁶²	Hu K...He F	15882182	2005
40	Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. ⁵³ ⁶²	Orejuela FJ...Hollier LM	15863148	2005
41	Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. ⁵³ ⁶²	Brustmann H	15782075	2005
42	Human telomerase RNA as endogenous control in endometrial tissue. ⁵³ ⁶²	Paul-Samojedny M...Wilczok T	15823123	2005
43	Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. ⁵³ ⁶²	Ozuysal S...Filiz G	14740230	2005
44	Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy. ⁵³ ⁶²	Sukhikh GT...Smetnik VP	16027816	2005
45	PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. ⁵³ ⁶²	Inaba F...Fujimori T	15583796	2005
46	Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. ⁵³ ⁶²	Bircan S...Ortac F	15800680	2005
47	Differences in serum bisphenol a concentrations in premenopausal normal women and women with endometrial hyperplasia. ⁵³ ⁶²	Hiroi H...Taketani Y	15644579	2004
48	Cellular retinol-binding protein-1 expression in endometrial stromal cells: physiopathological and diagnostic implications. ⁵³ ⁶²	Orlandi A...Czernobilsky B	15500655	2004
49	Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. ⁵³ ⁶²	Orbo A...Eklo K	15385114	2004
50	Multiple epithelial and nonepithelial tumors in hereditary nonpolyposis colorectal cancer: characterization of germline and somatic mutations of the MSH2 gene and heterogeneity of replication error phenotypes. ⁵³ ⁶²	Huang RL...Chu TY	15350299	2004

Sources

Genes for Endometrial Hyperplasia

Genes related to Endometrial Hyperplasia (0 elite genes):

(show all 31)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PGR	Progesterone Receptor	Protein Coding	25.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7922983 20199355 16831363 (more) 15863148 14735466 11873308 18839858 18528284 9159337 14747944 18287870 11251965 11443221 14501812 9221798 12684894 10756900 16575402
2	ESR1	Estrogen Receptor 1	Protein Coding	25.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7922983 16325240 16831363 (more) 17561234 11251965 1876529 10756900 15882182 18250990 14559803 11336777 8491764 15800680 9221798 19759112 11820567 16575402 14601091 12684894 9345349 16633364 14501812 20107426 18720455 16677694 18528284 15644579
3	PTEN	Phosphatase And Tensin Homolog	Protein Coding	25.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18788685 19224164 9635567 (more) 12459636 16764775 12405911 15948123 11873308 11818530 15385114 10955808 12649668 18632658 16909866 17085648 17466036 15583796 20079187 19696618 17009632
4	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	22.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8371007 16831363 17889878 (more) 20199355 19301987 16493257
5	ESR2	Estrogen Receptor 2	Protein Coding	20.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15882182 16325240 11820567
6	CABLES1	Cdk5 And Abl Enzyme Substrate 1	Protein Coding	20.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
7	CTNNB1	Catenin Beta 1	Protein Coding	20.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10411147 20079187
8	MLH1	MutL Homolog 1	Protein Coding	19.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11291077 12801268 10550333 (more) 14614055 11054716 17089036 12649668 16099019
9	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	19.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19419940
10	MSH6	MutS Homolog 6	Protein Coding	19.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12649668
11	MSH2	MutS Homolog 2	Protein Coding	18.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11291077 12801268 11054716 (more) 15350299 12649668
12	MMP26	Matrix Metallopeptidase 26	Protein Coding	18.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15350356
13	CDK2	Cyclin Dependent Kinase 2	Protein Coding	17.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17483252 19631369 12684894
14	RBP1	Retinol Binding Protein 1	Protein Coding	17.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16575402 15500655
15	MKI67	Marker Of Proliferation Ki-67	Protein Coding	17.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16831363 14740230 12684894 (more) 14601091
16	NCOA3	Nuclear Receptor Coactivator 3	Protein Coding	16.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16980945
17	NCOR1	Nuclear Receptor Corepressor 1	Protein Coding	16.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14601091
18	AR	Androgen Receptor	Protein Coding	15.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16325240
19	NCOA1	Nuclear Receptor Coactivator 1	Protein Coding	15.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14601091
20	CYP17A1	Cytochrome P450 Family 17 Subfamily A Member 1	Protein Coding	15.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16515644
21	TP53	Tumor Protein P53	Protein Coding	14.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	CDKN3	Cyclin Dependent Kinase Inhibitor 3	Protein Coding	14.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17466036 17085648 18788685 (more) 20199355
23	BCL2	BCL2 Apoptosis Regulator	Protein Coding	14.27	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	IFI27	Interferon Alpha Inducible Protein 27	Protein Coding	14.24	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17483252 19631369 9783852 (more) 12684894
25	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	14.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	CCND1	Cyclin D1	Protein Coding	13.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	13.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	PAX2	Paired Box 2	Protein Coding	13.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	HOXA10	Homeobox A10	Protein Coding	13.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	13.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	13.13	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Endometrial Hyperplasia

Sources

Expression for Endometrial Hyperplasia

Search GEO for disease gene expression data for Endometrial Hyperplasia.

Sources

Pathways for Endometrial Hyperplasia

Pathways related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 41)

#	Super pathways	Score	Top Affiliating Genes
1	Gene expression (Transcription) ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶ RNA Polymerase II Transcription ⁶⁶	14.02	PTEN PGR NCOR1 MSH2 MLH1 KRAS
2	Signal Transduction ⁶⁶	13.69	AR CDK2 CTNNB1 ESR1 ESR2 KRAS
3	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.65	NCOR1 NCOA3 NCOA1 MMP26 KRAS ESR2
4	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.57	RBP1 PTEN NCOR1 MSH6 MSH2 MLH1
5	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.32	PTEN NCOR1 NCOA3 KRAS ESR2 ESR1
6	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	12.92	PGR NCOR1 NCOA3 NCOA1 KRAS ESR2
7	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.78	PGR NCOR1 KRAS ESR1 CTNNB1
8	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.66	PTEN MSH6 MSH2 MLH1 KRAS CTNNB1
9	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.57	MSH6 MSH2 ESR2 ESR1 CDK2
10	DNA Damage ³	12.49	CDK2 MKI67 MLH1 MSH2 MSH6
11	Chromatin Regulation / Acetylation ³	12.38	NCOR1 NCOA3 NCOA1 AR
12	Base excision repair ⁷⁴ Show member pathways Abasic sugar-phosphate removal via the single-nucleotide replacement pathway ⁶⁶ APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway ⁶⁶ Cell cycle Transition and termination of DNA replication ²² Displacement of DNA glycosylase by APEX1 ⁶⁶ DNA mismatch repair ⁷⁴ Gap-filling DNA repair synthesis and ligation in GG-NER ⁶⁶ Mismatch Repair in Eukaryotes ⁶⁴ PCNA-Dependent Long Patch Base Excision Repair ⁶⁶ POLB-Dependent Long Patch Base Excision Repair ⁶⁶ Resolution of Abasic Sites (AP sites) ⁶⁶ Resolution of AP sites via the multiple-nucleotide patch replacement pathway ⁶⁶ Resolution of AP sites via the single-nucleotide replacement pathway ⁶⁶	12.38	MSH6 MSH2 MLH1 CDK2
13	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.29	ESR1 ESR2 NCOA1 NCOA3 NCOR1
14	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.27	CDK2 ESR1 NCOA1 NCOA3 NCOR1 PGR
15	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.19	PTEN PGR NCOA3 NCOA1 KRAS ESR2
16	Colorectal Cancer Metastasis ⁶⁴	12.13	MSH6 MSH2 MLH1 KRAS CTNNB1
17	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.06	PTEN NCOR1 NCOA1 CTNNB1 AR
18	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.05	PGR NCOR1 KRAS ESR1
19	Nuclear receptors ⁷⁴ Show member pathways Nuclear Receptor transcription pathway ⁶⁶ SUMOylation of intracellular receptors ⁶⁶	11.95	PGR NCOR1 ESR2 ESR1 AR
20	DNA damage response (only ATM dependent) ⁷⁴	11.87	PTEN KRAS CTNNB1
21	TGF-beta Signaling Pathways ⁶⁵	11.87	KRAS ESR2 ESR1 AR
22	p53 transcriptional gene network ⁷⁴	11.85	PTEN MSH2 MLH1 CDK2
23	Retinoblastoma gene in cancer ⁷⁴	11.79	RBP1 MSH6 CDK2
24	DNA IR-damage and cellular response via ATR ⁷⁴	11.75	CDK2 MLH1 MSH2
25	Head and neck squamous cell carcinoma ⁷⁴	11.69	CTNNB1 KRAS PTEN
26	Transcription Ligand-dependent activation of the ESR1/SP pathway ²² Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²²	11.67	NCOA3 NCOA1 ESR1
27	AP-1 transcription factor network ⁶¹	11.66	PTEN ESR1 CTNNB1
28	Regulation of nuclear SMAD2/3 signaling ⁶¹	11.64	NCOR1 NCOA1 ESR1 CDK2 AR
29	Integrated breast cancer pathway ⁷⁴	11.5	PTEN NCOA3 MSH6 MSH2 KRAS ESR1
30	FOXA1 transcription factor network ⁶¹	11.38	NCOA3 ESR1 AR
31	Integrated cancer pathway ⁷⁴	11.34	PTEN MSH6 MSH2 CDK2
32	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) ⁷⁴	11.3	PGR ESR2 ESR1
33	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.25	MSH6 MSH2 MLH1
34	Validated nuclear estrogen receptor alpha network ⁶¹	11.25	PGR NCOR1 NCOA3 NCOA1 ESR2 ESR1
35	Retinoic acid receptors-mediated signaling ⁶¹ Show member pathways Vitamins A and D - action mechanisms ⁷⁴	11.21	RBP1 NCOA3 NCOA1
36	Ovarian infertility ⁷⁴	11.21	CYP19A1 ESR2 MLH1 NCOR1 PGR
37	AHR Pathway ⁶⁴	11.17	NCOA3 NCOA1 ESR1
38	MNAR-PELP1 and Estrogen Receptor Interaction ⁶⁴	11.13	KRAS ESR2 ESR1
39	Validated nuclear estrogen receptor beta network ⁶¹	10.88	NCOA3 NCOA1 ESR2
40	Mammary gland development pathway - Puberty (Stage 2 of 4) ⁷⁴	10.8	PGR ESR1
41	Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics ⁶⁰	10.18	ESR2 ESR1 CYP19A1

Sources

GO Terms for Endometrial Hyperplasia

Cellular components related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	10.33	AR CDK2 CTNNB1 ESR1 ESR2 MKI67
2	chromatin	GO:0000785	10.16	PGR NCOR1 NCOA3 NCOA1 MSH6 ESR2
3	mismatch repair complex	GO:0032300	9.5	MSH2 MLH1
4	condensed chromosome	GO:0000793	9.35	MLH1 MKI67 CDK2
5	MutSalpha complex	GO:0032301	8.92	MSH6 MSH2

Biological processes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 19)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.14	CTNNB1 ESR1 ESR2 PTEN
2	cellular response to estradiol stimulus	GO:0071392	10.02	NCOA3 ESR2 ESR1
3	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.97	MSH6 MSH2 MLH1
4	mismatch repair	GO:0006298	9.95	MSH6 MSH2 MLH1
5	intracellular estrogen receptor signaling pathway	GO:0030520	9.88	ESR2 ESR1 AR
6	positive regulation of helicase activity	GO:0051096	9.86	MSH6 MSH2
7	isotype switching	GO:0045190	9.85	MSH6 MSH2 MLH1
8	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.83	MSH2 MLH1
9	epithelial cell differentiation involved in prostate gland development	GO:0060742	9.8	CTNNB1 AR
10	tertiary branching involved in mammary gland duct morphogenesis	GO:0060748	9.76	AR PGR
11	histone modification	GO:0016570	9.74	NCOA3 NCOA1 CDK2
12	positive regulation of epithelial cell proliferation involved in prostate gland development	GO:0060769	9.73	AR CTNNB1
13	somatic hypermutation of immunoglobulin genes	GO:0016446	9.73	MLH1 MSH2 MSH6
14	maintenance of DNA repeat elements	GO:0043570	9.69	MSH6 MSH2
15	prostate gland growth	GO:0060736	9.63	PTEN CYP19A1 AR
16	negative regulation of miRNA maturation	GO:1903799	9.58	NCOR1 ESR1
17	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.5	MSH2 MLH1
18	somatic recombination of immunoglobulin gene segments	GO:0016447	9.35	MSH6 MSH2 MLH1
19	intracellular steroid hormone receptor signaling pathway	GO:0030518	9.23	PGR ESR2 ESR1 AR

Molecular functions related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 19)

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin binding	GO:0003682	10.28	AR CTNNB1 ESR1 MLH1 MSH2 MSH6
2	RNA polymerase II-specific DNA-binding transcription factor binding	GO:0061629	10.1	NCOR1 NCOA3 NCOA1 CTNNB1 AR
3	transcription coactivator binding	GO:0001223	10.04	PGR ESR1 AR
4	nuclear estrogen receptor binding	GO:0030331	10.03	NCOA1 ESR1 CTNNB1
5	nuclear receptor activity	GO:0004879	9.97	PGR ESR2 ESR1 AR
6	lipid binding	GO:0008289	9.95	RBP1 PTEN PGR ESR2 ESR1 AR
7	ATP-dependent DNA damage sensor activity	GO:0140664	9.93	MSH6 MSH2 MLH1
8	nuclear steroid receptor activity	GO:0003707	9.91	PGR ESR2 ESR1
9	MutLalpha complex binding	GO:0032405	9.88	MSH6 MSH2
10	oxidized purine DNA binding	GO:0032357	9.88	MSH6 MSH2
11	nuclear receptor binding	GO:0016922	9.86	CTNNB1 NCOA1 NCOA3 NCOR1
12	estrogen response element binding	GO:0034056	9.85	ESR2 ESR1
13	nuclear estrogen receptor activity	GO:0030284	9.84	ESR1 ESR2
14	single guanine insertion binding	GO:0032142	9.83	MSH2 MSH6
15	single thymine insertion binding	GO:0032143	9.78	MSH6 MSH2
16	steroid binding	GO:0005496	9.76	PGR ESR2 ESR1 AR
17	mismatched DNA binding	GO:0030983	9.72	MSH6 MSH2 MLH1
18	enzyme binding	GO:0019899	9.62	PTEN PGR NCOA1 MSH6 MSH2 MLH1
19	guanine/thymine mispair binding	GO:0032137	9.43	MSH6 MSH2 MLH1